SKYEPHARMA PLC Form 6-K December 14, 2004

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a - 16 OR 15d - 16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of December, 2004

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F X Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

For Immediate Release

14 December

Edgar Filing: SKYEPHARMA PLC - Form 6-K

2004

SkyePharma PLC ("the Company")

Notification of Major Interest in Shares

In accordance with the Companies Act 1985 (as amended) the Company was informed by Fidelity Investments on 13 December 2004 that FMR Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries, both being non-beneficial holders ("Fidelity"), had increased their holding by 2,695,300 ordinary shares since their last filing on 03 December 2004. Fidelity's revised holding now amounts to 89,084,233 ordinary shares of 10p each, representing 14.31% of the issued share capital of the Company.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: <u>/s/</u> Douglas Parkhill

Name: Douglas Parkhill Title: Company Secretary

Date: December 14, 2004